Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 62,550 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 62,550 shares of the stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $35.94, for a total transaction of $2,248,047.00. Following the completion of the transaction, the director owned 2,188,935 shares in the company, valued at $78,670,323.90. This trade represents a 2.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $37.68 on Friday. The firm has a 50 day moving average of $37.44 and a 200 day moving average of $32.09. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $3.32 billion, a price-to-earnings ratio of -45.40 and a beta of 0.45. Liquidia Corporation has a 12-month low of $11.26 and a 12-month high of $46.67.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. The firm’s revenue was up 3072.4% compared to the same quarter last year. On average, research analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. purchased a new stake in shares of Liquidia during the 3rd quarter worth approximately $7,290,000. Caprock Group LLC purchased a new position in shares of Liquidia in the third quarter valued at $37,114,000. Apis Capital Advisors LLC bought a new stake in Liquidia in the third quarter worth $9,569,000. Farallon Capital Management LLC increased its position in Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after purchasing an additional 4,326,876 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Liquidia during the third quarter valued at $2,026,000. 64.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on LQDA shares. HC Wainwright boosted their price objective on Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, BTIG Research upped their price target on Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $43.44.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).